



## IVTScrip™ mRNA-Human APOB, (Cap 0, 2-Thio-UTP, 120 nt-poly(A))

Cat. No.: GTTS-WK22518MR

This product is for research use only and is not intended for diagnostic use.

### PRODUCT INFORMATION

#### Product overview

This product GTTS-WK22518MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It encodes the APOB protein. This product can be used in Epiblast cell-related researches.

#### Specifications

<b>Modified bases</b>	2-Thio-UTP
<b>5' Cap</b>	Cap 0
<b>Species</b>	Human
<b>RefSeq</b>	NM_000384.3
<b>Applications</b>	Gene therapy research
<b>Format</b>	Powder
<b>Quantity</b>	100 µg
<b>Purification</b>	Chromatography

### SPECIFICATIONS

<b>Modified bases</b>	2-Thio-UTP
<b>5' Cap</b>	Cap 0
<b>Species</b>	Human
<b>RefSeq</b>	NM_000384.3
<b>Applications</b>	Gene therapy research
<b>Format</b>	Powder
<b>Quantity</b>	100 µg
<b>Purification</b>	Chromatography

## GENE INFORMATION

<b>Alternative Names</b>	FLDB; FCHL2; LDLCQ4; apoB-48; apoB-100
<b>Description</b>	<p>This gene product is the main apolipoprotein of chylomicrons and low density lipoproteins (LDL), and is the ligand for the LDL receptor. It occurs in plasma as two main isoforms, apoB-48 and apoB-100: the former is synthesized exclusively in the gut and the latter in the liver. The intestinal and the hepatic forms of apoB are encoded by a single gene from a single, very long mRNA. The two isoforms share a common N-terminal sequence. The shorter apoB-48 protein is produced after RNA editing of the apoB-100 transcript at residue 2180 (CAA-&gt;UAA), resulting in the creation of a stop codon, and early translation termination. Mutations in this gene or its regulatory region cause hypobetalipoproteinemia, normotriglyceridemic hypobetalipoproteinemia, and hypercholesterolemia due to ligand-defective apoB, diseases affecting plasma cholesterol and apoB levels. [provided by RefSeq, Dec 2019]</p>